Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum

  • 450 Accesses

  • 13 Citations

Abstract

Despite the availability of different therapeutic options, canine visceral leishmaniosis (CVL) remains a challenging disease to treat. Recently miltefosine has been registered for use in dogs, and different studies have demonstrated its leishmanicidal effect. Moreover, it has been suggested that fluoroquinolones, compared to standard chemotherapeutic agents, could be an effective and pragmatic alternative to treat CVL. The efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum was assessed in vitro by incubating increasing concentrations of the drugs with a standard parasite inoculum. Miltefosine was significantly more efficacious than marbofloxacin (P < 0.05) against the two strains of L. infantum either alone or in combination with allopurinol. Both drugs were significantly (P < 0.05) more efficacious when associated with allopurinol than alone.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. Arthur G, Bittman R (1998) The inhibition of cell signalling pathways by anti-tumour ether lipids. Biochim Biophys Acta 1390:85–102

  2. Aste G, Di Tommaso M, Steiner JM (2005) Pancreatitis associated with N-methylglucamine therapy in a dog with leishmaniosis. Vet Res Comm 29(2):269–272

  3. Badolato R, Sacks DL, Savoia D, Musso T (1996) Leishmania major: infection of human monocytes induces expression of IL-8 and MCAF. Exp Parasitol 82:21–26

  4. Baneth G, Shaw SE (2002) Chemotherapy of canine leishmaniosis. Vet Parasitol 106(4):315–324

  5. Barratt G, Saint-Pierre-Chazalet M, Loiseau PM (2009) Cellular transport and lipid interactions of miltefosine. Curr Drug Metab 10:247–255

  6. Berkovic C, Grunwald U, Menzel W, Unger C, Hiddemann W, Fleer EA (1995) Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumor cells. Eur J Cancer 31:2080–2085

  7. Bianciardi P, Fasanella A, Foglia Manzillo V, Trotta T, Pagano A, Sorino S, Gradoni L, Oliva G (2004) The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitol Res 93:486–492. doi:10.1007/s00436-004-1170-0

  8. Bianciardi P, Brovida C, Valente M, Aresu L, Cavicchioli L, Vischer C, Giroud L, Castagnaro M (2009) Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicol Pathol 37(6):770–775

  9. Cavaliero T, Arnold P, Mathis A, Glaus T (1999) Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J Vet Intern Med 13(4):330–334

  10. Chakraborty AK, Majumder HK (1993) A type 1DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Biochem Biophys Res Commun 30:257–263

  11. Denerolle P, Bourdoiseau G (1999) Combination allopurinol and anti- 294 mony treatment versus antimony alone and allopurinol alone in 295 the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 296 13(5):413–415

  12. Ferreira JM, Guerra JA, Magalhães BM, Coelho LI, Maciel MG, Barbosa MG (2009) Chronic chagasic cardiopathy in Amazon region: an etiology to remember. Arq Bras Cardiol 93(6):e93–95, e107–109

  13. Gramiccia M, Gradoni L (2005) The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 35(11–12):1169–1180

  14. Ikeda-Garcia FA, Lopes RS, Ciarlini PC et al (2007) Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniosis submitted to treatment with meglumine antimoniate. Res Vet Sci 83:105–108

  15. Luz RI, Vermeersch M, Dujardin JC, Cos P, Maes L (2009) In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53(12):197–203

  16. Mandal G, Sarkar A, Saha P, Singh N, Sundar S, Chatterjee M (2009) Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys 46(1):86–92

  17. Manna L, Gravino AL, Picillo E, Decaro N, Buonavoglia C (2008) Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine. Ann N Y Acad Sci 1149:358–360

  18. Manna L, Vitale F, Reale S, Picillo E, Neglia G, Vescio F, Gravino AE (2009) Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J 182(3):441–445

  19. Maroli M, Gradoni L, Oliva G, Castagnaro M, Crotti A, Lubas G, Paltrinieri S, Roura X, Zini E, Zatelli A (2010) Guidelines for prevention of leishmaniasis in dogs. J Am Vet Med Assoc 236(11):1200–1206

  20. Mateo M, Maynard L, Vischer C, Bianciardi P, Mirò G (2009) Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitol Res 105:155–162

  21. Miró G, Oliva G, Cruz I, Cañavate C, Mortarino M, Vischer C, Bianciardi P (2009) Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet Dermatol 20(5–6):397–404

  22. Noli C, Auxilia ST (2005) Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16(4):213–232

  23. Prescott JF, Baggot DJ, Walker RD (2000) Fluoroquinolones. In: Giguère S et al (eds) Antimicrobial therapy in veterinary medicine, 3rd edn. Iowa State University Press/Ames, Iowa, pp 315–338

  24. Pujals G, Suñé-Negre JM, Pérez P, García E, Portus M, Tico JR, Miñarro M, Carrió J (2008) In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. Parasitol Res 102:1243–1247. doi:10.1007/s00436-008-0901-z

  25. Raether W, Seidenath H, Hofmann J (1989) Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo. Parasitol Res 75:412–413

  26. Rougier S, Vouldoukis I, Fournel S, Pérès S, Woehrlé F (2008) Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. Vet Parasitol 153:244–254

  27. Roura X (2010) Treatment of canine leishmaniosis. Proc of 2nd International Congress on Canine Leishmaniosis, 79–93

  28. Seifert K, Escobar P, Croft SL (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65(3):508–511

  29. Slunt KM, Grace JM, MacDonald TL, Pearson RD (1996) The effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother 40:706–709

  30. Torres M, Bardagi M, Roura X, Zanna G, Ravera I, Ferrer L (2011) Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol. Vet J 188(3):346–351. Epub 2010

  31. Unger C, Damenz W, Fleer EA, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G, Eibl H (1989) Hexadecylphosphocholine, a new ether lipid analogue: studies on the anti-neoplastic activity in vitro and in vivo. Acta Oncol 28:213–217

  32. Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, Maes L (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53(9):3855–3859

  33. Vouldoukis I, Drapier JC, Nussler AK, Tselentis Y, Da Silva OA, Gentilini M, Mossalayi DM, Monjour L, Dugas B (1996) Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the l-arginine nitric oxide pathway. Antimicrob Agents Chemother 40:253–256

  34. Vouldoukis I, Rougier S, Dugas B, Pino P, Mazier D, Woehrlè F (2006) Canine visceral leishmaniasis: comparison of in vitro activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet Parasitol 135:137–146

  35. Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B (2009) Miltefosine promotes IFN-dominated anti-leishmanial immune response. J Immunol 182:7146–7154

  36. Yoon S, Kim H, Lee Y, Kim S (2011) Bacteremia caused by Corynebacterium amycolatum with a novel mutation in gyrA gene that confers high-level quinolone resistance. Korean J Lab Med 31(1):47–48

  37. Zhang R, Shang L, Jin H, Ma C, Wu Y, Liu Q, Xia Z, Wei F, Zhu XQ, Gao H (2010) In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Parasitol Res. doi:10.1007/s00436-010-1906-y

Download references

Author information

Correspondence to Anna Maria Farca.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Farca, A.M., Miniscalco, B., Badino, P. et al. Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum . Parasitol Res 110, 2509–2513 (2012). https://doi.org/10.1007/s00436-011-2792-7

Download citation

Keywords

  • Allopurinol
  • Clinical Strain
  • Miltefosine
  • Leishmania Infantum
  • Meglumine Antimoniate